Abstracts Archive - Page 305 of 1683 - ATC Abstracts

2021 American Transplant Congress
De Novo Hepatitis B Infection Following Liver Transplant with Hepatitis B Core Antibody Positive Graft
L. J. Myhre¹, K. D. Watt², B. A. Aqel³
¹Pharmacy, Mayo Clinic, Rochester, MN, ²Gastroenterology/Hepatology, Mayo Clinic, Rochester, MN, ³Gastroenterology/Hepatology, Mayo Clinic, Phoenix, AZ
*Purpose: The risk of de novo HBV infection in liver transplant recipients of Hepatitis B core antibody (HBcAb) positive donor organs is tempered by availability…
2021 American Transplant Congress
Associations of Mammalian Target of Rapamycin Inhibitors with Post-Transplant Malignancies and All-Cause Mortality: Cause-Specific Competing Risks and Composite Outcomes Analyses
A. H. Santos¹, E. Bueno¹, M. A. Leghrouz¹, W. Xuerong²
¹University of Florida, Gainesville, FL, ²University of Rhode Island, Kingston, RI
*Purpose: We investigated the outcomes of malignancies and mortality associated with mammalian target of rapamycin inhibitor (MTORI) regimens in adult kidney transplant (KT) recipients (KTRs).*Methods:…
2021 American Transplant Congress
Single-Cell RNA-seq Identifies Intra-Graft Population Heterogeneity in Acute Heart Allograft Rejection in the Mouse
C. Wu¹, Y. Tang¹, X. Shi¹, X. He¹, X. Li²
¹The First Affiliated Hospital,Sun Yat-sen University, Guangzhou, China, ²Immunobiology & Transplant Sciences Houston Methodist Hospital, Houston, TX
*Purpose: Transplant rejection remains a major barrier to graft survival and involves a diversity of cell types. But the heterogeneity in a given cell type…
2021 American Transplant Congress
Role of Baseline PD-1 Checkpoint Inhibitor Pathway Expression in Bridge to Liver Transplant Hepatocellular Carcinoma
K. Nunez, T. Sandow, M. Hibino, A. Cohen, P. Thevenot
Ochsner Health, New Orleans, LA
*Purpose: Response to first line liver-directed therapy (LDT) in hepatocellular carcinoma (HCC) has important implications in both bridge to transplant (BTT) success as well as…
2021 American Transplant Congress
Measuring the Impact of Targeting FcRn-Mediated IgG Recycling on Donor-Specific Alloantibodies in a Sensitized NHP Model
M. Manook¹, W. Flores², R. Schmitz¹, Z. Fitch¹, J. Yoon¹, Y. Bae¹, B. I. Shaw¹, M. Harnois³, S. Permar³, A. Kirk¹, D. Magnani², J. Kwun¹, S. Knechtle¹
¹Duke Transplant Center, Duke University Medical Center, Durham, NC, ²Massbiologics, University of Massachusetts Medical School, Boston, MA, ³Human Vaccine Institute, Duke University Medical Center, Durham, NC
*Purpose: In transplantation, plasmapheresis and IVIg provide the mainstay of treatment directed at reducing or removing circulating donor specific antibody (DSA), yet both have limitations.…
2021 American Transplant Congress
A Comparison of Plasmapheresis Methods in the Treatment of Late Antibody Mediated Rejection
Y. Caliskan¹, H. Yazici², A. B. Dirim², E. Aksoy², S. Safak², N. Garayeva², S. Mirioglu², O. Yegit², O. A. Oto², Y. Ozluk³, S. Besisik⁴, A. Turkmen², K. Lentine¹
¹Saint Louis University, Saint Louis, MO, ²Division of Nephrology, Istanbul University, Istanbul, Turkey, ³Department of Pathology, Istanbul University, Istanbul, Turkey, ⁴Division of Hematology, Istanbul University, Istanbul, Turkey
*Purpose: Effective management to prevent allograft loss after late antibody mediated rejection (ABMR) in kidney transplant (KTx) recipients remains a vexing clinical challenge. While plasma…
2021 American Transplant Congress
Extreme Phenotype Sampling and Next Generation Sequencing to Identify Genetic Variants Associated with Tacrolimus Metabolism in African American Kidney Transplant Recipients
C. R. Dorr¹, B. Guo², B. Wu², J. Abrahante², D. Schladt³, R. Remmel², W. Guan², A. Muthusamy³, G. Onyeaghala³, N. Pankratz², A. Matas², R. Mannon⁴, W. Oetting², P. Jacobson², A. K. Israni³
¹Hennepin Healthcare Research Institute, Minneapolis, MN, ²University of Minnesota, Minneapolis, MN, ³Nephrology, Hennepin Healthcare Research Institute, Minneapolis, MN, ⁴University of Nebraska Medical Center, Omaha, NE
*Purpose: Tacrolimus (TAC) pharmacogenomics studies identified common genetic variants that alter TAC troughs suggesting strategic dosing for specific populations. Common variants and clinical factors explain…
2021 American Transplant Congress
Risk Classification Models for Kidney Graft Failure
M. G. Naik¹, K. Budde¹, D. Telmo Neves²
¹Medical Department, Division of Nephrology and Internal Intensive Care Medicine, Charité, Berlin, Germany, ²Intelligent Analytics for Massive Data, German Research Center for Artificial Intelligence, Berlin, Germany
*Purpose: Longterm graft survival after kidney transplantation is stagnant over the last decades. An individual risk assessment for graft failure is needed. In our project…
2021 American Transplant Congress
Initial Kidney Transplant Evaluations with Telehealth: Is it a Pandemic Only Practice?
A. Govil¹, E. Tims², C. Siemer², J. Harris², C. King², S. Shah¹, C. Thakar¹
¹Univ of Cincinnati, Cincinnati, OH, ²UC Health, Cincinnati, OH
*Purpose: COVID -19 pandemic presented an unprecedented challenge to health care systems. It disrupted the transplant processes including evaluations, especially in rural or other geographically…
2021 American Transplant Congress
The Role of Notch2 in Antibody-mediated Alloimmune Response
R. Benedetti Gassen¹, N. Murakami², T. J Borges¹, A. Al Jurdi¹, A. Alessandrini¹, L. V Riella¹
¹Center of Transplantation Science, Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA
*Purpose: Antibody mediated rejection is the leading cause of chronic allograft rejection. Developing a novel therapeutic target to inhibit chronic rejection is an urgent need…